Clinical Trials Logo
  1. Home
  2. Lung Cancer Stage III
  3. NCT03872661

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC — NIBCUN  

Lung Cancer Stage III Clinical Trial

Official title:
A Multicenter Phase II Trial of Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Clinical Trial Summary

The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.

Clinical Trial Description

Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with unresectable stage III non-small cell lung cancer (NSCLC), although surgery offers the chance of cure. With combined-modality therapy with radiation therapy and chemotherapy, the prognosis of stage III NSCLC remains poor. IBI308 (sintilimab) is a recombinant humanized anti-PD-1 monoclonal antibody. This study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03872661
Study type Interventional
Source Sun Yat-sen University
Contact Si-Yu Wang, MD
Phone +86 20 87343439
Email wsysums@163.net
Status Recruiting
Phase Phase 2
Start date March 1, 2019
Completion date March 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06003075 - Induction Chemo-Nivo in Unresectable Stage III NSCLC Phase 2
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05994339 - Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer Phase 2/Phase 3
Not yet recruiting NCT06060964 - Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management Early Phase 1
Recruiting NCT04991025 - Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Phase 2
Recruiting NCT06111807 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Active, not recruiting NCT03141359 - Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Phase 2
Recruiting NCT06086574 - Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
Not yet recruiting NCT05358691 - A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants Phase 1
Recruiting NCT06432972 - Accelerated Pulmonary Rehabilitation in the Preoperative Period N/A
Active, not recruiting NCT04364776 - Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Recruiting NCT05258448 - COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Active, not recruiting NCT04003246 - Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Phase 2
Completed NCT04057196 - Self-System Therapy for Older Adults With Lung Cancer N/A